Clinical Trial Update: Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating bivalirudin in HIT/HITTS has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heparin-induced Thrombocytopenia
• Heparin-induced Thrombocytopenia and Thrombosis Syndrome

Drugs mentioned

• Bivalirudin (bivalirudin)

Snippet

Sponsor: The Medicines Company | Conditions: Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome | Phase 4 | Status: WITHDRAWN